drugset / Trial / NCT01953731

A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)

NCT01953731

Phase 1 Completed 15 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

This study will compare the plasma pharmacokinetics of a single 125mg oral dose of palbociclib in the presence and absence of rifampin-mediated enzyme induction in a fixed-sequence two-period study.

Timeline

Start
2013-10
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule 125 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.